Neurocrine Biosciences, Inc. (0K6R.L)
USD 109.75
(1.72%)
USD 109.75
(1.72%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.84 Billion USD | 26.06% |
| 2022 | 1.46 Billion USD | 30.94% |
| 2021 | 1.11 Billion USD | 8.05% |
| 2020 | 1.03 Billion USD | 32.68% |
| 2019 | 780.7 Million USD | 74.91% |
| 2018 | 446.35 Million USD | 178.32% |
| 2017 | 160.37 Million USD | 867.33% |
| 2016 | -20.9 Million USD | -48.96% |
| 2015 | -14.03 Million USD | 2.56% |
| 2014 | -14.4 Million USD | -32.34% |
| 2013 | -10.88 Million USD | -126.19% |
| 2012 | 41.54 Million USD | -46.34% |
| 2011 | 77.41 Million USD | 131.08% |
| 2010 | 33.5 Million USD | 1034.47% |
| 2009 | 2.95 Million USD | -25.71% |
| 2008 | 3.97 Million USD | 224.75% |
| 2007 | 1.22 Million USD | -96.88% |
| 2006 | 39.23 Million USD | -68.33% |
| 2005 | 123.88 Million USD | 45.45% |
| 2004 | 85.17 Million USD | -38.76% |
| 2003 | 139.07 Million USD | 670.73% |
| 2002 | 18.04 Million USD | -56.25% |
| 2001 | 41.24 Million USD | 145.69% |
| 2000 | 16.78 Million USD | -11.19% |
| 1999 | 18.9 Million USD | 6.78% |
| 1998 | 17.7 Million USD | -35.4% |
| 1997 | 27.4 Million USD | 35.64% |
| 1996 | 20.2 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 614.1 Million USD | 6.87% |
| 2024 Q1 | 502.49 Million USD | -0.83% |
| 2024 Q2 | 574.6 Million USD | 14.35% |
| 2023 Q2 | 441.2 Million USD | 7.11% |
| 2023 FY | 1.84 Billion USD | 26.06% |
| 2023 Q1 | 411.9 Million USD | 1.88% |
| 2023 Q4 | 506.7 Million USD | 3.92% |
| 2023 Q3 | 487.6 Million USD | 10.52% |
| 2022 Q1 | 306 Million USD | -0.62% |
| 2022 Q4 | 404.3 Million USD | 5.89% |
| 2022 Q3 | 381.8 Million USD | 2.25% |
| 2022 Q2 | 373.4 Million USD | 22.03% |
| 2022 FY | 1.46 Billion USD | 30.94% |
| 2021 Q3 | 291.8 Million USD | 2.1% |
| 2021 Q4 | 307.9 Million USD | 5.52% |
| 2021 Q2 | 285.8 Million USD | 22.29% |
| 2021 FY | 1.11 Billion USD | 8.05% |
| 2021 Q1 | 233.7 Million USD | -4.61% |
| 2020 Q2 | 300 Million USD | 27.66% |
| 2020 FY | 1.03 Billion USD | 32.68% |
| 2020 Q3 | 255.8 Million USD | -14.73% |
| 2020 Q4 | 245 Million USD | -4.22% |
| 2020 Q1 | 235 Million USD | -2.73% |
| 2019 FY | 780.7 Million USD | 74.91% |
| 2019 Q2 | 181.97 Million USD | 32.56% |
| 2019 Q3 | 219.86 Million USD | 20.82% |
| 2019 Q4 | 241.6 Million USD | 9.89% |
| 2019 Q1 | 137.27 Million USD | 5.63% |
| 2018 Q4 | 129.95 Million USD | -13.48% |
| 2018 Q2 | 96.05 Million USD | 36.95% |
| 2018 Q1 | 70.13 Million USD | -25.19% |
| 2018 FY | 446.35 Million USD | 178.32% |
| 2018 Q3 | 150.2 Million USD | 56.38% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | 60.34 Million USD | 861.76% |
| 2017 FY | 160.37 Million USD | 867.33% |
| 2017 Q4 | 93.75 Million USD | 55.38% |
| 2017 Q2 | 6.27 Million USD | 0.0% |
| 2016 FY | -20.9 Million USD | -48.96% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | 15 Million USD | 0.0% |
| 2015 Q2 | - USD | -100.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | 19.76 Million USD | 0.0% |
| 2015 FY | -14.03 Million USD | 2.56% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | -14.4 Million USD | -32.34% |
| 2014 Q1 | - USD | -100.0% |
| 2013 Q1 | 730 Thousand USD | -96.67% |
| 2013 FY | -10.88 Million USD | -126.19% |
| 2013 Q4 | 730 Thousand USD | 0.14% |
| 2013 Q3 | 729 Thousand USD | -0.14% |
| 2013 Q2 | 730 Thousand USD | 0.0% |
| 2012 Q3 | 9.35 Million USD | -11.47% |
| 2012 Q4 | 21.94 Million USD | 134.55% |
| 2012 FY | 41.54 Million USD | -46.34% |
| 2012 Q1 | 11.26 Million USD | 1.41% |
| 2012 Q2 | 10.56 Million USD | -6.2% |
| 2011 Q2 | 12.15 Million USD | -2.84% |
| 2011 Q4 | 11.11 Million USD | -73.32% |
| 2011 FY | 77.41 Million USD | 131.08% |
| 2011 Q3 | 41.63 Million USD | 242.47% |
| 2011 Q1 | 12.51 Million USD | -8.38% |
| 2010 Q3 | 14.44 Million USD | 211.18% |
| 2010 Q2 | 4.64 Million USD | 516.6% |
| 2010 Q1 | 753 Thousand USD | 1.76% |
| 2010 FY | 33.5 Million USD | 1034.47% |
| 2010 Q4 | 13.65 Million USD | -5.47% |
| 2009 Q4 | 740 Thousand USD | 0.95% |
| 2009 Q3 | 733 Thousand USD | 0.0% |
| 2009 FY | 2.95 Million USD | -25.71% |
| 2009 Q1 | 747 Thousand USD | 2.47% |
| 2009 Q2 | 733 Thousand USD | -1.87% |
| 2008 Q1 | 1.75 Million USD | 229.14% |
| 2008 Q2 | 734 Thousand USD | -58.08% |
| 2008 Q3 | 761 Thousand USD | 3.68% |
| 2008 FY | 3.97 Million USD | 224.75% |
| 2008 Q4 | 729 Thousand USD | -4.2% |
| 2007 FY | 1.22 Million USD | -96.88% |
| 2007 Q4 | 532 Thousand USD | -1.48% |
| 2007 Q3 | 540 Thousand USD | 1025.0% |
| 2007 Q2 | 48 Thousand USD | -53.85% |
| 2007 Q1 | 104 Thousand USD | -98.9% |
| 2006 Q4 | 9.44 Million USD | 778.96% |
| 2006 Q1 | 19.47 Million USD | 38.02% |
| 2006 FY | 39.23 Million USD | -68.33% |
| 2006 Q3 | 1.07 Million USD | -88.38% |
| 2006 Q2 | 9.24 Million USD | -52.54% |
| 2005 Q1 | 11.86 Million USD | -35.82% |
| 2005 FY | 123.88 Million USD | 45.45% |
| 2005 Q2 | 33.16 Million USD | 179.58% |
| 2005 Q3 | 64.74 Million USD | 95.2% |
| 2005 Q4 | 14.11 Million USD | -78.21% |
| 2004 Q4 | 18.48 Million USD | -46.73% |
| 2004 Q3 | 34.7 Million USD | 130.59% |
| 2004 Q2 | 15.04 Million USD | -11.17% |
| 2004 Q1 | 16.94 Million USD | -37.57% |
| 2004 FY | 85.17 Million USD | -38.76% |
| 2003 FY | 139.07 Million USD | 670.73% |
| 2003 Q4 | 27.13 Million USD | -7.26% |
| 2003 Q3 | 29.25 Million USD | -34.93% |
| 2003 Q2 | 44.96 Million USD | 19.23% |
| 2003 Q1 | 37.71 Million USD | 872.56% |
| 2002 FY | 18.04 Million USD | -56.25% |
| 2002 Q4 | 3.87 Million USD | -22.18% |
| 2002 Q1 | 4.95 Million USD | -61.37% |
| 2002 Q2 | 4.22 Million USD | -14.73% |
| 2002 Q3 | 4.98 Million USD | 17.89% |
| 2001 Q4 | 12.83 Million USD | -40.57% |
| 2001 Q3 | 21.59 Million USD | 548.83% |
| 2001 Q2 | 3.32 Million USD | -4.59% |
| 2001 Q1 | 3.48 Million USD | -15.44% |
| 2001 FY | 41.24 Million USD | 145.69% |
| 2000 FY | 16.78 Million USD | -11.19% |
| 2000 Q1 | 3.29 Million USD | -31.31% |
| 2000 Q3 | 5.88 Million USD | 69.24% |
| 2000 Q4 | 4.12 Million USD | -29.92% |
| 2000 Q2 | 3.47 Million USD | 5.49% |
| 1999 FY | 18.9 Million USD | 6.78% |
| 1999 Q4 | 4.8 Million USD | -15.79% |
| 1999 Q2 | 4.2 Million USD | 0.0% |
| 1999 Q1 | 4.2 Million USD | -14.29% |
| 1999 Q3 | 5.7 Million USD | 35.71% |
| 1998 Q2 | 2.7 Million USD | -40.0% |
| 1998 Q3 | 5.6 Million USD | 107.41% |
| 1998 Q4 | 4.9 Million USD | -12.5% |
| 1998 FY | 17.7 Million USD | -35.4% |
| 1998 Q1 | 4.5 Million USD | -31.82% |
| 1997 Q4 | 6.6 Million USD | 1.54% |
| 1997 Q1 | 9.1 Million USD | -5.21% |
| 1997 FY | 27.4 Million USD | 35.64% |
| 1997 Q3 | 6.5 Million USD | 27.45% |
| 1997 Q2 | 5.1 Million USD | -43.96% |
| 1996 Q2 | 5.7 Million USD | 137.5% |
| 1996 FY | 20.2 Million USD | 0.0% |
| 1996 Q1 | 2.4 Million USD | 0.0% |
| 1996 Q3 | 2.5 Million USD | -56.14% |
| 1996 Q4 | 9.6 Million USD | 284.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -83304.063% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -611621.854% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 2267.903% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -10566.898% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 590323.642% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -12387.495% |
| Imunon, Inc. | -720 Thousand USD | 256681.552% |
| Dynavax Technologies Corporation | 182.11 Million USD | -914.403% |
| Editas Medicine, Inc. | -99.52 Million USD | 1956.161% |
| FibroGen, Inc. | 128.9 Million USD | -1333.16% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 19412.147% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 609802.97% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -69.022% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -252.731% |
| Verastem, Inc. | -62 Thousand USD | 2979777.419% |
| Zoetis Inc. | 5.83 Billion USD | 68.334% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 78.536% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 4175.896% |
| Homology Medicines, Inc. | -7.22 Million USD | 25655.402% |
| Nektar Therapeutics | 53.47 Million USD | -3354.505% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 632771.233% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 9478.141% |
| Perrigo Company plc | 1.68 Billion USD | -9.938% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -2428.364% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 93.035% |
| Illumina, Inc. | 2.74 Billion USD | 32.675% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 87.865% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 64.738% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -18296.734% |
| Waters Corporation | 1.76 Billion USD | -4.895% |
| Biogen Inc. | 7.3 Billion USD | 74.701% |
| Evolus, Inc. | 140.52 Million USD | -1214.632% |
| Adicet Bio, Inc. | -6.09 Million USD | 30395.179% |
| bluebird bio, Inc. | -4.03 Million USD | 45941.191% |
| Geron Corporation | -123.5 Million USD | 1595.834% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -21.709% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -410.289% |
| Myriad Genetics, Inc. | 476.4 Million USD | -287.783% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 563.247% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 14.83% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 6027.298% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 2.992% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 83.653% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 46.684% |
| OPKO Health, Inc. | 318.12 Million USD | -480.711% |
| Exelixis, Inc. | 1.75 Billion USD | -5.106% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -288.196% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -655.475% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -137.298% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -190.065% |
| Blueprint Medicines Corporation | 236.58 Million USD | -680.864% |
| Insmed Incorporated | 239.63 Million USD | -670.922% |
| TG Therapeutics, Inc. | 219.1 Million USD | -743.146% |
| Incyte Corporation | 3.44 Billion USD | 46.307% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -437.191% |